BioHarvest Sciences Inc.: financial statements

BHSTNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.32

November 19, 2026Market cap $30M

What Ploutos Investor adds for BioHarvest Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+65.0% a year over 2 years

Line202320242025Average a year
Revenue $13M$25M$35M+65.0%
Cost of revenue $7.0M$11M$14M+41.2%
Gross profit $5.6M$14M$20M+90.6%
Operating income -$10.0M-$7.0M-$5.6M
Net income -$13M-$13M-$11M
Earnings per share, basic -$0.93-$0.80-$0.60
Margins
Gross margin 44.5%55.4%59.3%
Operating margin -78.6%-27.7%-16.2%
Net margin -99.1%-51.3%-32.3%

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

The full analysis

What do BioHarvest Sciences's filings show?

These are BioHarvest Sciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BHST's financials

Didn't find what you were looking for?

Ask us
How much revenue did BHST have in 2025?

BioHarvest Sciences had revenue of $35M and net income of -$11M in fiscal 2025, a net margin of -32.3%.

How much debt does BHST have?

On December 31, 2025 BioHarvest Sciences had total assets of $48M, debt of $149.0K and shareholders' equity of $25M.

How much free cash flow does BHST have?

In fiscal 2025 BioHarvest Sciences had cash from operations of -$7.2M and spent $2.4M on capital expenditure, leaving -$9.6M of free cash flow.

Where are the figures from?

From BioHarvest Sciences Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.